December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Comparative Efficacy of Prednisolone Acetate Vs. Rimexolone in the Treatment of Anterior Uveitis HLA-B27 Positive
Author Affiliations & Notes
  • G Padilla-Aguilar
    Uveitis Asociacion para Evitar la Ceguera en México IAP Mexico City Mexico
  • L Arellanes-Garcia
    Mexico City Mexico
  • C Espinoza-Martinez
    Mexico City Mexico
  • P Navarro-Lopez
    Mexico City Mexico
  • Footnotes
    Commercial Relationships   G. Padilla-Aguilar, None; L. Arellanes-Garcia, None; C. Espinoza-Martinez, None; P. Navarro-Lopez, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4283. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G Padilla-Aguilar, L Arellanes-Garcia, C Espinoza-Martinez, P Navarro-Lopez; Comparative Efficacy of Prednisolone Acetate Vs. Rimexolone in the Treatment of Anterior Uveitis HLA-B27 Positive . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4283.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To compare the efficacy and safety of prednisolone acetate 1% and 1% rimexolone ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27 + patients. Methods: Sixty - nine AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% (Group A) or rimexolone 1% (Group B). All patients showed mild to moderate anterior chamber inflammation. Intraocular pressure and inflammation were recorded weekly during six weeks. It was a prospective, randomized, double blind, clinical trial. Results: There was no a statistically significant difference among group A and B when anterior chamber flare and cells were measured. In both groups the IOP raised above the basal value at the first week (12.5% for prednisolone and 10.25% for rimexolona), however at the end of the study the IOP was lower in the group B (6.1% above the basal value) than in the Group A ( 19.66% above the basal value) this difference was not statistically significant (p = 0.55). Conclusion: Rimexolone 1% is as effective as Prednisolone acetate 1% in the treatment of mild to moderate AAU HLA-B27 +. Final IOP in both groups was similar.

Keywords: 612 uveitis-clinical/animal model • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 437 inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.